Abrdn Life Sciences Investors DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Abrdn Healthcare Investors, Abrdn Life Sciences Investors, Abrdn Healthcare Opportunities Fund, and Abrdn World Healthcare Fund have issued a joint proxy statement detailing their upcoming annual shareholder meetings on May 27, 2026, primarily for the election of Trustees.
NYSE
Abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn Healthcare Opportunities Fund, and abrdn World Healthcare Fund will hold annual shareholder meetings on May 28, 2025, to elect trustees.
NYSE
DEFA14A: abrdn Life Sciences Investors Urges Shareholders to Respond to Important Operating Initiatives
abrdn Life Sciences Investors (formerly Tekla Life Sciences Investors) is reaching out to shareholders to request their input on important operating initiatives.
NYSE
abrdn Life Sciences Investors (HQL) will hold its annual shareholder meeting on June 25, 2024, to vote on the election of two Class B Trustees and a shareholder proposal regarding the annual election of all trustees.